Ponatinib versus Bosutinib in 3rd-Line Chronic Phase - Chronic Myeloid Leukemia (CP-CML): Indirect Comparison of Efficacy Using Iterative Proportional Fitting

Open-label trials of ponatinib (PACE, NCT01207440) and bosutinib (NCT00261846; published by Khoury 2012) in third-line patients with CP-CML suggest that ponatinib is more efficacious than bosutinib in this setting, but clinical and reimbursement decisions call for data from head-to-head trials. As such studies are unlikely, we indirectly compared efficacy in the two trials using Iterative Proportional Fitting (IPF) to adjust for differences in baseline characteristics.